Dr. Myers has more than 30 years of industry experience in the drug delivery and specialty pharmaceutical sectors. He has served CEO of Innocoll, Inc. and was responsible for taking that company public in 2014. He has also served as president of the drug delivery division of West Pharmaceutical Services, president of pharmaceutical operations for Fuisz Technologies (Biovail) and has held executive positions in Flamel Technologies and Elan Corporation. Dr. Myers earned his Ph.D. in Chemistry from the University College Cork. Dr. Myers serves on the Board of Directors of Sonoran Biosciences as well as on the Advisory Boards for two Penn State startup companies, Cranial Devices and Gradient T.

Ms. Denise Carter has over 30 years of experience in the drug delivery and specialty pharmaceutical industries. Prior to Quoin, Ms. Carter was executive vice president of business development and corporate affairs at Innocoll, Inc., vice president of business development of the drug delivery division of West Pharmaceuticals, and she has held executive positions at Eurand and Fuisz Technologies (Biovail) Ms. Carter earned her MBA from Wharton School of Business, University of Pennsylvania and a B.S. in Chemistry from the College of William and Mary.

Gordon joined Quoin in November of 2021. He brings over 30 years of finance experience and has served as CFO of both private and publicly traded companies. In addition, Mr. Dunn has deep experience in investment banking and private equity. Over the last five years he has served as Chief Financial Officer for several private companies, most recently with Qured, a UK based healthcare provider, from 2020 to 2021. Mr Dunn also served as CFO of Innocoll Inc. from 2012-2016. Prior to joining Innocoll, Mr. Dunn had 20 years’ experience in investment banking and private equity, including over ten years managing the private equity funds of NewSmith Capital, and nine years at Merrill Lynch where he served as co-head of the European Private Equity Group and Director of Equity Capital Markets. Mr. Dunn received a B.A. from Stanford University and a J.D. from New York University School of Law.

After graduating from Georgetown School of Medicine and Harvard Law School, Dr. Langer spent over 35 years in the pharmaceutical industry at Eli Lilly, Abbott, Searle, GSK and as President at Dr. Reddy’s, NA. He was a Director at Sirna Therapeutics (acquired by Merck), Ception Therapeutics (acquired by Cephalon), Transkaryotic Therapies (acquired by Shire), Pharmacopeia (acquired by Ligand), Cytogen (acquired by EUSA Pharma) and Delcath Systems. Dr. Langer is a Director at Myriad Genetics, Dicerna Pharmaceuticals and Pernix Therapeutics. He is a Clinical Psychiatry Professor at Georgetown and serves on the Dean’s Advisory Board of Harvard Law School.

Ms. Leong has worked across four continents in valuation and transactions in sale, IPO, float, financial modeling, internal controls and raising capital. She has experience analyzing business plans, performing market analyses, preparing financial projections, developing valuation models, advising on equity transactions, mergers, acquisitions and corporate restructurings. Currently, Ms. Leong is Head of Finance for LoanStreet. Previously, she was US lead for the Asset Liability Committee at RBC Capital Markets. At National Australia Bank, Ms. Leong was promoted to VP of Capital Insights. She has an MBA from Wharton, a BCom and a BA from the University of Melbourne.

Currently, Mr. Culverwell is Chairman of HOX Therapeutics, focusing on prostate cancer research. He is also NED of Safeguard Biosystems, in late stage development of a low cost, high throughput, molecular diagnostic system. Previously, Mr. Culverwell was NED at Atlantic Healthcare, developing treatments for ulcerative colitis. He was NED and Chairman of Audit at Amryt Pharmaceuticals, which focuses on rare diseases including Hypercholesterolemia and Epidermolysis Bullosa. He was also NED at Innocoll AG. Mr. Culverwell’s experience includes Director and Head of European Healthcare and Pharmaceutical Equity Research at Hoare Govett/ABN Amro. And was FVP of Global Healthcare Research at Merrill Lynch/Bank of America.

With 30 years of pharmaceutical industry experience, Mr. Cooper has held roles in operational, corporate development and general management. Currently, he is Chief of Strategy and Corporate Development at Resonea. Formerly, he was President at Boulder Cove and Executive VP of Corporate Development at Medicis Pharmaceutical. Earlier he was with Schein and GD Searle. His leadership experience is in clinical research, product development, supply chain, business development and executive management in a broad range of therapeutic areas including dermatology, aesthetics, allergy, sleep apnea, stroke and orphan drugs. Mr. Cooper currently serves on the board of Sonoran Biosciences, Bioenvision and board observer for several specialty pharmaceutical companies. He serves as a commercial partner of Tech Launch Arizona, the technology advancement arm of the University of Arizona.

In his 40-year career, Mr. Sember has been COO or CEO of five diverse pharmaceutical companies ranging from drug discovery tool providers, to therapeutically-focused biotechnology companies, to medical devices. For example, at Marion Laboratories (later Marion Merrell Dow) Mr. Sember handled roles including sales, research and R&D program management. As Executive VP of Business Development for Élan Corporation, he was responsible for strategic collaborations, mergers and acquisitions. Mr. Sember has consulted for numerous companies and has extensive public and private board experience. Currently Mr. Sember serves as Chair of the Screening Panel and Board member for the number-one-ranked Desert Angels, a Tucson, AZ-based group of angel investors.